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Abstract
Introduction: This study aimed to determine the homing potential and fate of epidermal neural crest stem cells 
(eNCSCs) derived from hair follicles, and bone marrow-derived stem cells (BMSCs) of mesenchymal origin, in a 
lipopolysaccharide (LPS)-induced inflammatory lesion model in the rat brain. Both eNCSCs and BMSCs are easily 
accessible from adult tissues by using minimally invasive procedures and can differentiate into a variety of neuroglial 
lineages. Thus, these cells have the potential to be used in autologous cell-replacement therapies, minimizing immune 
rejection, and engineered to secrete a variety of molecules.
Methods: Both eNCSCs and BMSCs were prelabeled with iron-oxide nanoparticles (IO-TAT-FITC) and implanted either 
onto the corpus callosum in healthy or LPS-lesioned animals or intravenously into lesioned animals. Both cell types 
were tracked longitudinally in vivo by using magnetic resonance imaging (MRI) for up to 30 days and confirmed by 
postmortem immunohistochemistry.
Results: Transplanted cells in nonlesioned animals remained localized along the corpus callosum. Cells implanted 
distally from an LPS lesion (either intracerebrally or intravenously) migrated only toward the lesion, as seen by the 
localized MRI signal void. Fluorescence microscopy of the FITC tag on the nanoparticles confirmed the in vivo MRI data,
Conclusions: This study demonstrated that both cell types can be tracked in vivo by using noninvasive MRI and have 
pathotropic properties toward an inflammatory lesion in the brain. As these cells differentiate into the glial phenotype 
and are derived from adult tissues, they offer a viable alternative autologous stem cell source and gene-targeting 
potential for neurodegenerative and demyelinating pathologies.
Introduction
A number of CNS injury and neurodegenerative diseases
result in varying degrees of cell death and neuroinflam-
mation. Cell-based therapies involving stem cells aim to
replace these lost cells or repair damaged areas, thus pro-
viding functional recovery. However, before the potential
of stem cell-based therapies can be realized, it is impor-
tant to understand the behavior of these cells after
implantation in vivo and the practicalities of different
routes of administration. Such longitudinal studies are
best performed by using noninvasive in vivo MRI cell-
tracking protocols and indeed are a prerequisite for cell-
replacement therapy for translation to the clinic.
An important factor in clinical translation of cell-based
therapy is the selection of appropriate cell types for trans-
plantation. Stem cells derived from adult tissues have a
number of advantages, including their utility in autolo-
gous stem cell therapy, where they not only reduce the
need for immunosuppression but are harvested relatively
easily in the clinic. Current literature indicates the prom-
ising repair potential of two adult stem cell types: epider-
mal neural crest cells and bone marrow mesenchymal
stem cells. Neural crest cells (NCCs) constitute a popula-
tion of neuroepithelial, migratory, multipotent stem cells
that give rise to most of the peripheral nervous system
during development, including dorsal root ganglia (DRG)
neurons, DRG satellite glia, and Schwann cells. NCCs
also give rise to melanocytes and skeletal structures of the
face. Until recently, NCCs were considered a transient
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cell population that existed only during development.
However, recent work demonstrated that multipotent
NCCs persist into adulthood within the stem-cell niche
of hair follicles, and these adult-resident cells have been
termed epidermal neural crest stem cells (eNCSC) [1].
Because eNCSCs retain the neuroglial differentiation
potential of embryonic NCCs [1] and can be harvested
from hairy skin by using a minimally invasive procedure,
they are an attractive cell type to consider for autologous
cell-replacement therapies to repair the injured CNS.
The other cell type with a similar potential for autolo-
gous cell-based applications in CNS repair is mesenchy-
mal stem cells (MSCs) derived from the bone marrow.
MSCs derived from marrow stromal cells differentiate
into tissues of mesodermal lineage, such as fat, bone, and
cartilage [2], but can also differentiate along neuroglial
lineages [3]. In the uninjured rat brain, bone marrow-res-
ident cells continuously contribute to neural populations,
including neurons, microglia, and occasionally astrocytes
in the dentate gyrus and periventricular zones [4]. How-
ever, the numbers of resident MSCs homing to CNS
lesions are small. By harvesting, expanding in vitro, and
then re-introducing autologous cells systemically, more
stem cells are likely to home to the sites of CNS injuries,
where they can provide therapeutic benefit. For example,
human MSCs injected intravenously into rats after spinal
cord injury were found to infiltrate mainly into the vent-
rolateral white matter tracts, where they differentiated
into oligodendrocytes [5]; however, the migration of the
cells was assessed only at the end point instead of the lon-
gitudinal imaging used in the present study. In stroke and
inflammatory-lesion models of adult brain injury in rats,
as well as in human stroke studies, injected MSCs have
been reported enter the brain from the circulation and
stimulate host oligodendrogenesis and remyelination [6-
9]. Although it must be emphasized that the differentia-
tion of BMSCs into neural phenotypes is somewhat con-
troversial, their homing ability may be useful in gene or
growth-factor delivery.
Several studies have demonstrated the migration of
stem cells after intravenous injection (Chen et al., 2001;
Garbuzova-Davis et al., 2003; Jendelova et al., 2004;
Takeuchi et al., 2007) in models of neurodegeneration.
However, the models used in these studies involved
mainly ischemia and compression injury, which give rise
to more severe lesions. This study aims to assess stem cell
behavior in more moderate cerebral insults. In addition,
although earlier studies clearly demonstrate the potential
of eNCSCs and BMSCs for neural repair, they provide
only a 'snapshot,' postmortem view of what is happening
to the transplanted cells. Therefore, the aims of this study
were to use longitudinal in vivo MR imaging, followed by
histologic analysis, to monitor the migratory potential
and resulting fate of eNCSCs and BMSCs, by using two
routes of administration (cerebral implantation or intra-
venous injection) in a lipopolysaccharide (LPS) lesion
model of CNS inflammation.
Materials and methods
Animals
All surgical procedures were carried out under a UK
Home Office Project Licence in accordance with the UK
(Animals) Scientific Procedures Act 1986. Healthy adult
(250 to 300 g) male Sprague-Dawley rats (Harlan, UK)
were acclimatized for a week on a regular diet and equal
light/dark cycle.
Cell purification
Rat eNCSCs were obtained from the hair bulbs of vibrissa
whiskers, as described previously [1,10]. In brief, 2-week-
old Sprague-Dawley rat pups were killed by carbon diox-
ide inhalation and their whisker pads removed and placed
in DMEM. Individual whiskers were isolated and
trimmed to leave only the bulge region, and the covering
connective tissue was removed. Dissected hair-bulge
explants were then allowed to attach to collagen-coated
T75 flasks for 4 hours in a minimal volume of 10% FCS-
DMEM and were subsequently topped up with 5 ml 10%
FCS-DMEM. Medium was changed every third day. After
4 to 5 days in culture, neural crest cells were observed
migrating away from the hair-bulge explants (Figure 1).
At this stage, the hair-bulge explants were carefully
removed with an 18G needle to minimize contamination
with later-migrating cell types, such as keratinocytes.
After 10 days in vitro, cells were prelabeled with IO-TAT-
FITC nanoparticles and implanted, as described later.
Immunocytochemistry at the time of injection demon-
strated that more than 60% of the cells were Sox10 immu-
nopositive eNCSCs (Figure 1c). Confirmation of their
neuroglial lineage was confirmed by supplementing 10-
day-old cultures with 10 ng/ml neuregulin for 4 days,
which caused eNCSCs to differentiate into S100-positive
Schwann cells (Figure 1d).
Bone marrow-derived stem cells were harvested from
adult (300 g) Sprague-Dawley rats. Animals were killed,
the hindlimbs were shaved, and the femurs and tibias
removed aseptically. Then 10% FCS-DMEM was used to
flush the marrow shafts by using a 26G needle, and the
bone marrow was harvested. After centrifugation (1,500
rpm, 3 minutes), the pellet was resuspended in 10% FCS-
DMEM. Cells were then cultured in previously prepared
PLL-coated dishes, in DMEM supplemented with 10%
FCS and gentamicin (25 μg/ml). Flasks were incubated at
37°C and 7.5% CO2. Two days after plating, the dishes
were washed 3 times with 10% FCS-DMEM to remove
nonadherent hematopoietic cells. Subsequently, 100%
culture medium was changed every 2 days to maintain
the health of the culture. To confirm the mesenchymal
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Figure 1 Phenotype of implanted cells. (a-d) Neural crest stem cells (NCSCs); (e-j) bone marrow stem cells (BMSCs). (a) Sox10 in situ of the bulge 
region of a hair bulb, revealing the NCSC population. (b) Cell emigration from a hair bulb (HB) after 7 days in vitro. (c) Sox10 immunostaining of the 
NCSCs (low numbers of Sox10-negative cells are shown with arrowheads). (d) NCSCs cultured for 14 days, with the final 4 days in 10 ng/ml neuregulin, 
then immunostained for the Schwann cell marker S100 (occasional S100-negative cells marked with arrowheads). BMSCs were (e) vimentin+, (f) CD90+, 
and (g) CD45-, consistent with a mesenchymal phenotype. (h) Undifferentiated rat bone marrow cells exhibit a stromal phenotype in culture. (i) Adi-
pogenic differentiation of rat bone marrow-derived stem cells showing the presence of intracellular lipid vacuoles (stained with Oil Red O). (j) Osteo-
genic differentiation of rat bone marrow showing the presence of calcification (stained with Alizarin Red). Scale bars: 50 μm (b-d), 20 μm (e, f), 10 μm 
(g), and 200 μm (h-j).
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phenotype of the BMSCs, cells were differentiated into
osteogenic or adipogenic lineages for 14 days in culture
and were fixed with 4% paraformaldehyde for 10 minutes
and stained with either 40 mM Alizarin Red (Sigma) or
fresh Oil Red O (Sigma) according to Zhao et al. [11] (Fig-
ure 1i, j). The phenotype of the cells was also confirmed
by using vimentin, CD90, and CD45 immunocytochemis-
try (Figure 1e-g).
Cell labeling with iron oxide nanoparticles
Dextran-coated iron oxide nanoparticles were prepared
in house according to the method of Josephson et al. [12].
The nanoparticles were conjugated with both FITC, for
histologic analysis and TAT peptide as a membrane-
transfection agent. Cells were prelabeled with IO-TAT-
FITC nanoparticles (mean diameter, 20 nm)in vitro over-
night. The final IO incubation solution comprised 10 μg
Fe/ml/100,000 cells, in accordance with our previous
studies [13,14].
LPS lesioning and cell implantation
Animals were divided into three groups for each cell type:
cells implanted onto the corpus callosum of healthy ani-
mals (n = 3), cells implanted 3 mm medial to LPS injec-
tion (n = 5), and cells injected intravenously 1 week after
LPS injection (n = 2).
Animals were immunosuppressed with cyclosporine A
(Sandimmun, Sandoz, UK) administered intraperitone-
ally at a dose of 2.5 mg/kg daily from the day of cell
implantation until death. Thermoregulation of the rat
was monitored during surgery with a rectal probe and
kept constant at 37°C with a feedback-controlled warm-
ing blanket (Harvard Apparatus, Massachusetts, USA).
For the animal lesioning, 5 μl of 1-μg/μl lipopolysaccha-
ride (LPS) (in saline) was injected onto the corpus callo-
sum of healthy animals (250 g) by using a small-animal
stereotactic frame (Kopf Instruments, Tujunga, USA) at
the following coordinates derived from a rat brain atlas
[15]: A-P, + 1.0 mm; L-M, -1.0 mm; D-V, -3.2 mm. Before
surgery, a single-cell suspension was prepared in DMEM
supplemented with 0.04 mg/ml bovine pancreas DNase
(Sigma-Aldrich) to prevent clumping of the cells. Then
50,000 cells in a volume of 5 μl were injected at a rate of 1
μl/min (Figure 2). The needle was maintained in situ for 2
minutes before and 5 minutes after cell injection to allow
intracranial pressure equalization. For implantation into
the healthy animals, stereotactic coordinates were as fol-
lows (relative to the bregma); corpus callosum: A-P, + 1.0
mm; L-M, -2.4 mm; D-V, -3.2 mm. When cells were
implanted into the LPS-lesioned animals, the following
stereotactic coordinates were used: A-P, +1.0 mm; L-M, -
4.0 mm; D-V, -4.0 mm to maintain a substantial distance
between the cells and LPS.
Serial MRI
Animals were anesthetised, and thermoregulation was
monitored during the MRI. In vivo serial imaging was
performed at 9.4 T (Oxford Instruments, Abingdon, UK)
by using a Varian console (Varian, Palo Alto, CA, USA).
The head of the animal was positioned inside a 63-mm
(internal diameter) birdcage coil. To visualize the
implanted cells, a spin-echo T2-weighted image was
acquired by using the following parameters: TR = 3,500
msec; TE = 40 msec; matrix = 256 × 128; FOV = 40 × 40
mm; slice thickness = 0.5 mm; with four averages, 20
slices per scan. Each animal was scanned weekly (on aver-
age, 4 times in total); with each scan lasting 30 minutes.
T2 measurements were obtained by using a spin-echo
sequence with a fixed repetition time (TR) and a varying
echo time (TE). The following parameters were used: TR
= 3,500 msec; matrix = 256 × 128; FOV = 40 × 40 mm;
slice thickness = 0.5 mm; number of averages = 1, and
varying TEs of 12, 20, 30, 40, 50, 60, 70, 80, and 100 msec.
T2 maps were reconstructed for each slice by using an
ImageJ plug in (11). Regions of interest (ROIs) were
drawn on standard anatomic images and then trans-
formed into T2 maps. Average signal intensity (SI) values
for each ROI at each TE value were transferred to Graph-
Pad Prism (GraphPad Software, La Jolla, CA, USA); T2
relaxation curves were then created for each ROI. To
visualize and confirm the neuroinflammatory lesion
(edema induced by LPS) in the brain, T2* fast-spin-echo
sequences were used with the following parameters: TR =
3,000 msec; TEeffective = 24 msec with a train of eight
echoes; FOV = 40 × 40 mm; matrix = 256 × 128; averages
= 16; slice thickness = 0.5 mm; number of averages = 8.
Histologic analysis
Animals were intracardially perfused with 4% paraform-
aldehyde and the brains removed. Brains were cryopro-
tected in 20% sucrose before being snap-frozen by using
precooled isopentane. The 10-μm coronal sections were
cut by using a cryostat (Leica Microsystems GmbH, Wet-
zlar, Germany) and placed on glass slides. The iron oxide
nanoparticles were visualized by using a Prussian blue
staining procedure by incubating the sections overnight
in a solution of 10% potassium ferrocyanide and 20%
hydrochloric acid (vol/vol).
Immunocytochemistry/immunohistochemistry/in situ 
hybridization
The following primary antibodies were used: rabbit anti-
Sox10 (1:10, Calbiochem), rabbit anti-GFAP (1:200,
Sigma), CD90 (1:100, BD), CD45 (1:100, BD), S-100β
(1:300, Dako), and Vimentin (1:50, Sigma). Cultured
eNCSCs and BMSCs were fixed in 4% paraformaldehyde
for 20 minutes, permeabilized with 0.1% Triton X-100 in
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PBS for 10 minutes, blocked with 10% normal sheep
serum for 1 hour, and then processed with primary anti-
body. BMSCs grown in the presence of the osteogenic or
adipogenic media were stained with 40 mM Alizarin Red
or fresh Oil Red O, respectively.
Brain cryosections were blocked in 10% serum (species
of secondary antibody), 0.1% Triton-X for 1 hour and
then processed with the primary antibody. Primary anti-
bodies (described earlier) were prepared in 10% serum/
PBS and incubated overnight at 4°C. The lectin, Isolectin
B4, was used to detect microglia (IB4; 1:50, Sigma). The
secondary antibody in 10% serum/PBS was added for 1
hour at 4°C. Secondary antibodies were Alexa 488 goat
anti-rabbit and Alexa 594 goat anti-mouse (Invitrogen),
both applied at a 1:200 dilution. Finally, nuclei were coun-
terstained with DAPI for 10 minutes. Coverslips were
mounted on the sections by using Vectashield (Vector
Laboratories, Burlingame, USA) as an antifade mountant.
Tissue in situ hybridization for Sox10 mRNA was per-
formed on the bulge region of vibrissae whiskers, accord-
ing to standard protocols [16].
Results
Phenotypes of donor cells
Neural crest cells characteristically express the nuclear
transcription factor Sox10 [1]. Hair-follicle bulge explants
were processed for in situ hybridization with a Sox10
antisense riboprobe, which revealed a ring of staining
corresponding to the niche of adult eNCSCs (Figure 1a).
Between 50% and 60% of cultured cells that emigrated
from bulge explants within 7 days (Figure 1b) had Sox10-
immunopositive nuclei (Figure 1c). None of the cultured
cells was immunopositive for the glial cell marker glial
fibrillary acidic protein (GFAP; not shown), consistent
with previous studies [1]. However, cells could be driven
to an S-100 immunopositive glial fate by supplementing
10 day-old cultures with 10 ng/ml neuregulin for 4 days
(Figure 1d).
The phenotype of the BMSCs was confirmed with
immunocytochemistry and differentiation assays. The
harvested BMSCs were found to be vimentin+, CD90+,
and CD45- (Figure 1e-g). The mesenchymal lineage of the
rat BMSCs was confirmed by their ability to differentiate
readily into adipocytes and osteoblasts [17] (Figure 1h-j).
Previous studies within the group showed that labeling
with IO-TAT-FITC does not affect the proliferation or
differentiation of BMSCs, nor did it induce apoptosis
(data not shown).
Cell implantation into unlesioned brains
Two groups of animals were stereotactically implanted
with either eNCSCs or BMSCs (50,000 cells in 5 μl) onto
Figure 2 Localized CNS inflammation model with LPS, with different routes of cell administration. eNCSCs or BMSCs were either implanted 
onto the corpus callosum of healthy animals, or implanted onto the corpus callosum 3 mm medial to LPS lesion or injected intravenously 1 week after 
LPS lesioning.
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the corpus callosum in the right hemisphere. Both
implanted cell types remained visible as an MRI hypoin-
tense region for at least 30 days (Figure 3). The cells dis-
played some lateral and posterior migration away from
the injection site along the white-matter tract of the cor-
pus callosum The average lateral spatial distribution mea-
sured on MR images for eNCSCs and BMSCs was 0.92 ±
0.36 mm (mean ± SEM) and 1.04 ± 0.11 mm (mean ±
SEM), respectively, and this appeared to be spread
equally on either side of the injection site. This indicates
that the corpus callosum environment does not impose
any inherent directionality on the migration of these
implanted cells. Previous studies within the group have
shown that either implanted labeled dead cells or free
iron-oxide nanoparticles are cleared away by the local
environment within 30 days, leaving little residual MRI
signal void (see Supplementary data 1 in Additional file
1). This suggests that our detection of signal void, of more
than 30 days after implantation in the current experi-
Figure 3 Stem cells implanted into the brains of unlesioned animals. (a) Implanted eNCSCs (top row) and BMSCs (bottom row) after IO-TAT-FITC 
labeling and stereotactic implantation (arrows) onto the corpus callosum remained visible by MRI in the same animals for at least 30 days. The spread 
of the cells appeared to be equally distributed both laterally and medially from the injection site, suggesting no inherent preference of the cells to 
migrate in one particular direction in the unlesioned brain. False-colored inserts allow better visualization of the hypointense regions. Implanted eNC-
SCs after IO-TAT-FITC labeling and stereotactic implantation onto the corpus callosum were visible by postmortem histology for a minimum of 30 
days. (b) Implanted NCSCs (green) on the corpus callosum demonstrated some GFAP (red) glial differentiation (arrows). Nuclear stain DAPI (blue). (c) 
Implanted NCSCs migrate laterally along the white-matter tract of the corpus callosum for approximately 450 μm. (d) Implanted NCSCs (green) did 
not become S-100+ (a marker of mature Schwann cells). Insert shows mature S-100+ Schwann cells in a section of peripheral nerve, immunostained 
under identical conditions as a positive control. Scale bars: 20 μm (b, d), and 100 μm (c).
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ments, most likely represents surviving, live, transplanted
cells.
Postmortem histology confirmed the persistence of the
implanted FITC+ cells and was anatomically consistent
with the MR images (Figure 3a). After direct implantation
onto the corpus callosum, the FITC+ eNCSCs were seen
to have been distributed longitudinally at a distance of
approximately 450 μm (Figure 3c). To determine whether
any of the transplanted stem cells had differentiated along
the neuroglial lineage, the brain sections were immunos-
tained with glial and neural specific antibodies. Limited
GFAP+ differentiation of FITC+ cells (Figure 3b) was
noted, but no staining for FITC+/βIII-tubulin (not
shown); that is, no neuronal differentiation was detected.
Moreover, the FITC + implanted eNCSCs showed no evi-
dence of S-100 differentiation (a marker of mature
Schwann cells) (Figure 3d). The data are therefore consis-
tent with eNCSC differentiation along a glial pathway, but
only to immature nonmyelinating Schwann cells.
Intracerebral implantation into the LPS-lesion model
The LPS lesion appeared as a hyperintense signal void on
a T2*- weighted MR image and led to a demyelination con-
firmed by absence of Luxol Blue staining (Figure 4).
Immediately after injection of LPS, animals were stereot-
actically implanted with 50,000 IO-TAT-FITC labeled
cells (five rats with eNCSCs, three rats with BMSCs). The
site of implantation was located 3 mm distally (but a
greater distance along the curve of the corpus callosum)
from the LPS lesion. In vivo MRI imaging at various inter-
vals after implantation demonstrated that both cell types
migrated along the white-matter tract of the corpus callo-
sum preferentially toward the LPS lesion, thus demon-
strating pathotropic cellular behavior (Figure 5). No
evidence was found of cells continuing to migrate beyond
the lesion or migrating into the contralateral hemisphere.
MR signal void, due to an influx of IO-labeled cells, could
be detected in the lesion site for up to 28 days with eNC-
SCs and for up to 94 days for the BMSCs.
To confirm the differential MR relaxation properties
induced by the labeled cells at both the injection and
lesion sites compared with the surrounding tissue, a
number of varying T2 relaxation values were determined.
The T2 values of different brain regions were determined
from the T2 maps, generated by varying the echo time
(TE) during the MR imaging. It was found that cells at the
injection site (26.1 ± 6.3; mean ± SD) and the lesion site
(27.3 ± 1.7; mean ± SD) had similar T2 values, but these
were lower than either the corpus callosum (34.0 ± 1.4;
mean ± SD) or the striatum (45.0 ± 3.8; mean ± SD), thus
allowing the cells to be discriminated from the surround-
ing tissue on MR images thus further confirming migra-
tion of the cells toward the lesion from the implantation
site (see Supplementary data 2 in Additional file 2).
Postmortem histology of FITC labeling confirmed the
MR data that implanted cells had migrated along the cor-
pus callosum to the lesion site (Figure 5). Some eNCSCs
were still present at the injection site, and of those cells
that had migrated, some exhibited GFAP immunoreactiv-
ity, indicating glial differentiation. Around 20% of FITC+
cells were also IB4+ (a microglia/macrophage marker).
However, it is unclear whether this represents: differenti-
ation of cells into microglia, engulfment of live cells, dead
cells, or of released IO-TAT-FITC nanoparticles. Never-
theless, the remaining population of FITC+ cells were not
colocalized with IB4, indicating that the signal void was
not from incidental labeling of microglia.
Intravenous cell injection into an LPS-lesioned model
Having demonstrated that CNS-implanted stem cells
migrate to a local inflammatory lesion, it was important
to extend these studies to determine whether a less-inva-
sive route for delivery of stem cells toward a central lesion
site was feasible. Therefore, 50,000 cells were injected
Figure 4 LPS injection causes an inflammatory focal demyelinated lesion. (a) A T2*-weighted MRI sequence was used to visualize the LPS-in-
duced localized inflammatory response, shown as a hyperintense signal (arrow) on the right side of the corpus callosum1 week after lesioning. (b) 
Influx of microglia in the right corpus callosum after injection of LPS, confirmed by isolectin B4 staining (red). (c) Demyelinated lesion in the corpus 
callosum after LPS insult, confirmed by Luxol Blue (blue) and cresyl violet (purple) staining at 1 week. Scale bars: 1 mm (b, c).
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intravenously via the tail vein to assess their migrational
potential from the peripheral vasculature to a LPS lesion
in the brain.
Within 24 hours after intravenous administration of
stem cells, a MR signal void developed at the site of the
LPS injection/lesion (Figure 6). This signal void became
more defined over the following 8-day period (Figure 6).
Animals were killed 10 days after administration of the
IO-TAT-FITC-labeled cells. In one animal, the number of
IO-TAT-FITC+ cells, on alternate tissue sections (to
reduce the possibility of double counting), was counted at
the LPS-lesion site. It was estimated that approximately
4,000 of 50,000 cells administered intravenously had
homed to the LPS-lesioned area from the peripheral vas-
Figure 5 Stem cells implanted in the brains of lesioned animals. (a) eNCSCs (top row) and BMSCs (bottom row) were stereotactically implanted 3 
mm lateral to an LPS inflammatory lesion (arrows). The cells migrated toward the LPS lesion and were seen as a darkening of the right side of the corpus 
callosum False-colored inserts allow better visualization of the hypointense regions. (b) In coronal sections, both IO-TAT-FITC-labeled cell types were ob-
served to have migrated from the implantation site (arrow 1) toward the LPS-lesion site (arrow 2) along the corpus callosum. Some cells were still present 
along the corpus callosum (arrow 3). IB4 staining (arrow; second column; red) showed that some FITC label had been taken up by microglia. GFAP staining 
(arrows; third column, red) showed some glial differentiation of implanted cells. Scale bars: 1 mm (b; IO-TAT-FITC), 20 μm (b; IB4, GFAP).
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culature, thus representing 8% of the total eNCSCs
injected. Furthermore, the cells were found to have
spread along the corpus callosum (Figure 6).
The FITC+ BMSCs also were found to be distributed
throughout the right corpus callosum over a distance of
3.6 mm around the LPS-demyelinated lesion area. An
issue with cell-implantation studies is whether the MRI
reports on either nanoparticle-labeled cells or free IO-
TAT-FITC nanoparticles released on cell death and sub-
sequently engulfed by resident microglia or transient
Figure 6 Stem cells, administered intravenously, home to an inflammatory lesion in the brain. (a) An LPS lesion was induced on the right cor-
pus callosum, followed by intravenous administration of 50,000 IO-TAT-FITC-labelled eNCSCs (top row) or BMSCs (bottom row). Both cell types mi-
grated to the LPS-lesion site (arrows) from the peripheral vasculature within 24 hours of administration. False-colored inserts show better the 
hypointense regions. (b) Both cells types migrated to the LPS lesion after intravenous injection. The IO-TAT-FITC signal demonstrated that the cells 
had migrated to the lesioned brain area from the peripheral vasculature 24 hours after injection (arrows; first column). Some FITC signal was detected 
in IB4+ resident macrophages/microglia (arrows; second column; red). Similarly, limited differentiation into GFAP+ glia was seen (arrows; third column; 
red). Scale bars: 1 mm (b; IO-TAT-FITC), 20 μm (b; IB4, GFAP).
Jackson et al. Stem Cell Research & Therapy 2010, 1:17
http://stemcellres.com/content/1/2/17
Page 10 of 12
macrophages, which then migrated to the lesion. Isolec-
tin-B4 staining indicated that a small proportion (about
20%) of the cells were double positive for both FITC and
IB4. However, most FITC+ cells were IB4-, suggesting that
the majority of cells within the lesion site were the
peripherally transplanted stem cells that had migrated to
the lesion from the circulation.
Discussion
Increasing clinical interest exists in the use of transplant-
able stem cells as a means of repairing neurodegenerative
disease or for gene delivery. The success of such
approaches will be dependent on not only the source of
donor stem cells and their expansion in vitro, but also
their mode of delivery, where localized surgical delivery
to the brain carries inherent risks of morbidity. Studies
have begun to evaluate the clinical efficacy of using intra-
venously administered bone marrow stem cells in dis-
eases such as spinal cord injury [18]. This study
demonstrates that MRI is a useful technique that allows
longitudinal noninvasive monitoring of stem cell migra-
tion in the brains of individual animals, giving important
information on cell dynamics and interactions with the
host CNS.
Implanted eNCSCs or BMSCs were visible as a hypoin-
tense region in T2 MRI images, allowing them to be
tracked as they migrated within the brain. Implanted cells
remained visible at the lesion site by MRI for the duration
of the experiment (up to 13 weeks). Stem cells implanted
directly into the brain were found to migrate preferen-
tially along the major white matter tracts in both healthy
and lesioned animals. In animals with a focal inflamma-
tory lesion, the transplanted cells displayed unidirectional
pathotropic migration to the lesion, where they ceased
migrating and remained visible on MRI for several
months. Moreover, and of potential benefit for clinical
applications, both cell types similarly displayed migration
to a focal inflammatory brain lesion from the peripheral
vasculature.
Several studies have demonstrated the migration of
stem cells after intravenous administration in models of
neurodegeneration [19-22]. However, those models
involved cerebral ischemia and compression injury,
which result in a more severe lesion. Our study has
shown that relatively minor, focal lesions provide suffi-
cient cues to attract stem cells from the peripheral vascu-
lature. Our LPS-lesion model induces a focal
demyelination, resulting in an influx of microglia; such
lesions have been shown to stimulate the release of cytok-
ines such as IL-1β, TNF, and IL-6 [23], which may have
provided the chemoattractant signals for eNCSCs and
BMSCs. The migration of transplanted stem cells
through the brain parenchyma may also be aided by their
secretion of matrix metalloproteases (MMPs), because
BMSCs require MMP1 to migrate toward human gliomas
[24]. Because no donor cells could be detected in other
regions of the brain, this suggests that the cells were not
simply trapped within the cerebral blood vessels, but
were responding specifically to chemotactic factors
released from the lesion. It has been reported that eNC-
SCs are not migratory when transplanted into the
lesioned spinal cord [25], whereas our work shows that
eNCSCs have homing properties similar to those of
BMSCs and invade brain lesion from the peripheral vas-
culature. This suggests that the local CNS environment
may have an important effect in regulating NCSC attrac-
tion and invasion, possibly by altering the expression of
NCSC chemokine receptors or proteases essential for cell
migration.
Although the intravenous administration route has
obvious clinical advantages, we found that one challenge
of using this route will be to get sufficient cells to the
lesion for therapeutic benefit. Thus, we estimate that only
about 8% of the intravenously injected stem cells
migrated to the LPS lesion. By contrast, more than 10
times this number of stem cells reached the lesion site
after intracranial administration some 3 mm from the
lesion site. It will be of interest to determine whether
other vascular routes, such as the carotid artery, might
increase the proportion of injected stem cells that enter
the brain-lesion site. It will also be of interest to examine
whether stem-cell engraftment can be maximized by
changing the postlesion timing of cell delivery. Any delay
in delivery, sufficient to permit the in vitro expansion of
autologous stem cells, would obviously be desirable from
a practical and clinical perspective.
Concerning the fate of the administered stem cells, we
found that BMSCs and eNCSCs were able to adopt glial
fates in the brain, although we did not detect stem cell-
derived neurons. A previous study demonstrated that
BMSCs have the ability to differentiate into astrocyte-like
and oligodendrocyte-like cells after implantation into an
ischemic lesion [17]. A separate study, by using eNCSCs
in a in rat spinal cord crush lesion model, detected lim-
ited S-100 differentiation of implanted eNCSCs, indica-
tive of mature Schwann cells [25]. We did not detect S-
100 differentiation of the implanted eNCSCs in our focal
LPS-lesion model, although several implanted cells
expressed GFAP, an early marker of glial differentiation
for both astrocytes and immature Schwann cells [26]. It
remains unclear whether, had the experiment been
allowed to proceed for a longer period, the implanted
eNCSCs in our model would eventually mature into
myelinating Schwann cells.
Previous studies within the group have shown that dead
cells, prelabeled with IO-TAT-FITC, are cleared away
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from the local area and do not contribute to a signal void
(see Supplementary data 1 in Additional file 1). In addi-
tion, and consistent with this study, previous studies
using live stem cells have shown that whereas a few of the
cells are engulfed by IB4+ microglia, the majority remain
nonphagocytosed after BMSC implantations into a
rodent model of Parkinson disease [14].
Conclusions
In summary, this study has shown by using a noninvasive
longitudinal in vivo imaging modality, that two stem-cell
types, with the potential for autologous cell therapy and
gene targeting in CNS injury and neurodegenerative dis-
eases, have pathotropic properties in a focal demyelinat-
ing brain lesion when they are administered by either the
intracerebral or the intravenous routes. Moreover, this
work reinforces that intravenous delivery is a viable clini-
cal option for the delivery of cell-based therapies, with
obvious clinical advantages over direct CNS injection.
Additional material
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